Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993347 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| SCHEMBL23756600 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| SCHEMBL29668817 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| Hydrochloric Acid SCHEMBL18228119 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| Hydrochloric Acid SCHEMBL18228121 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| Hydrochloric Acid SCHEMBL18228516 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| Hydrochloric Acid SCHEMBL20186895 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| SCHEMBL18795036 | 0.89 | CHRNB2 (0.53) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| SCHEMBL2687753 | 0.85 | SIGMAR1 (0.48) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 | |
| SCHEMBL5051448 | 0.85 | SIGMAR1 (0.48) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4103558-A1 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-3749672-B1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2022-07-27 | — | — | EP | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| CN-103827101-B | Dicyclo dihydroquinoline-2-ketone derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-07 | — | — | CN | disclosed |
| EP-3078662-A1 | PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016073891-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-2727910-B1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | ARRAY BIOPHARMA INC (US) | 2016-03-16 | — | — | EP | disclosed |
| CN-104245674-A | Novel phenyl-tetrahydroisoquinoline derivatives | HOFFMANN LA ROCHE | 2014-12-24 | — | — | CN | disclosed |
| EP-2727910-A1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | Array Biopharma, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2573087-A1 | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2209778-B1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2008118718-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2003014089-A1 | AMINOTETRAHYDROISOQUINOLINE DERIVATIVES AS ANALGESICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | CHRNB2 4817/4885CHRNA4 4875/4885SIGMAR1 4315/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | CHRNB2 2299/4885CHRNA4 2426/4885SIGMAR1 3683/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | CHRNB2 2299/4885CHRNA4 2426/4885SIGMAR1 3683/4885 |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CHRNB2 4331/4885CHRNA4 4335/4885SIGMAR1 4558/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | CHRNB2 648/4885CHRNA4 596/4885SIGMAR1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.